PL4103178T3 - Sposoby leczenia choroby fabry'ego - Google Patents

Sposoby leczenia choroby fabry'ego

Info

Publication number
PL4103178T3
PL4103178T3 PL21753606.9T PL21753606T PL4103178T3 PL 4103178 T3 PL4103178 T3 PL 4103178T3 PL 21753606 T PL21753606 T PL 21753606T PL 4103178 T3 PL4103178 T3 PL 4103178T3
Authority
PL
Poland
Prior art keywords
methods
fabry disease
treating fabry
treating
disease
Prior art date
Application number
PL21753606.9T
Other languages
English (en)
Inventor
Nina SKUBAN
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL4103178T3 publication Critical patent/PL4103178T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL21753606.9T 2020-02-10 2021-02-10 Sposoby leczenia choroby fabry'ego PL4103178T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972392P 2020-02-10 2020-02-10
PCT/US2021/017446 WO2021163183A1 (en) 2020-02-10 2021-02-10 Methods of treating fabry disease

Publications (1)

Publication Number Publication Date
PL4103178T3 true PL4103178T3 (pl) 2026-05-11

Family

ID=77272302

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21753606.9T PL4103178T3 (pl) 2020-02-10 2021-02-10 Sposoby leczenia choroby fabry'ego

Country Status (16)

Country Link
US (1) US20210251972A1 (pl)
EP (2) EP4732901A2 (pl)
JP (1) JP2023513700A (pl)
KR (1) KR20220150902A (pl)
AU (1) AU2021218578A1 (pl)
CA (1) CA3167476A1 (pl)
DK (1) DK4103178T3 (pl)
ES (1) ES3066136T3 (pl)
FI (1) FI4103178T3 (pl)
HR (1) HRP20260399T1 (pl)
LT (1) LT4103178T (pl)
PL (1) PL4103178T3 (pl)
PT (1) PT4103178T (pl)
RS (1) RS67913B1 (pl)
SM (1) SMT202600143T1 (pl)
WO (1) WO2021163183A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
EP3749307B1 (en) 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4289476A3 (en) * 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
WO2021026447A1 (en) 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2017298376A1 (en) * 2016-07-19 2019-03-07 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naive and ERT-experienced patients

Also Published As

Publication number Publication date
US20210251972A1 (en) 2021-08-19
RS67913B1 (sr) 2026-04-30
DK4103178T3 (da) 2026-03-30
EP4732901A2 (en) 2026-04-29
ES3066136T3 (en) 2026-05-11
FI4103178T3 (fi) 2026-03-23
EP4103178B1 (en) 2025-12-24
JP2023513700A (ja) 2023-04-03
LT4103178T (lt) 2026-04-10
AU2021218578A1 (en) 2022-08-25
KR20220150902A (ko) 2022-11-11
EP4103178A4 (en) 2024-03-20
PT4103178T (pt) 2026-03-30
EP4103178A1 (en) 2022-12-21
CA3167476A1 (en) 2021-08-19
WO2021163183A1 (en) 2021-08-19
HRP20260399T1 (hr) 2026-05-08
SMT202600143T1 (it) 2026-05-12

Similar Documents

Publication Publication Date Title
ES3066136T3 (en) Methods of treating fabry disease
IL304273A (en) Compositions and methods for treating Fabry disease
IL277500A (en) A method for treating fibrotic disease
IL288677A (en) Methods for treating Fabry disease in patients with kidney failure
HUE064761T2 (hu) Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
IL315503A (en) Treatment methods
ZA202400405B (en) Methods of treating neurological diseases
IL320711A (en) Treatment methods
IL290983A (en) Treatment methods
IL290892A (en) Methods for treating vascular diseases
GB202201824D0 (en) Methods of treatment
GB202001353D0 (en) Treatment of skin conditions
ES3065434T3 (en) Methods of treating fabry patients having renal impairment
IL286099A (en) Methods of treating the disease using levoketoconazole
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
IL268111A (en) Methods of treating pain
GB202118007D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
GB202005874D0 (en) Methods of treatment
IL325944A (en) Treatment methods
GB202102950D0 (en) Method of treatment